Clik here to view.
Groundbreaking eBooks from Japan’s Leading Medical Publisher, MEDICUS...
OSAKA, Japan MEDICUS SHUPPAN, Publishers Co., Ltd. (Osaka, Japan, President: Sobi Hasegawa) has been engaged in the business of publication/education for physicians/nurses in Japan for over 40 years...
View ArticleClik here to view.
GEN1 Biotechnology Raises AUD$8m (USD$6.3m)
ADELAIDE, Australia GEN1 Biotechnology Pty Ltd, a biopharmaceutical manufacturer based in Adelaide, Australia, has completed an AUD$8m (USD$6.3m) funding round, with an expected closing during...
View ArticleClik here to view.
FDA同意WIN联合会启动3种靶向药物用于转移性非小细胞肺癌一线治疗的临床试验
法国维勒瑞夫 (美国商业资讯) — 美国食品药品管理局(FDA)已核准WIN联合会(WIN)启动一种新型治疗方法的临床研究，该方法采用3种靶向药物联合，用于晚期非小细胞肺癌(NSCLC)患者的一线治疗。该研究名称为“理性创新基因组学延长生存期” (Survival Prolongation by Rationale Innovative Genomics,...
View ArticleClik here to view.
WINコンソーシアムが転移性非小細胞肺がんのファーストライン治療での分子標的薬3剤併用療法の臨床試験開始の承認をFDAより取得
仏ビルジュイフ （ビジネスワイヤ） — WINコンソーシアム（WIN）は、米食品医薬品局（FDA）より、進行性非小細胞肺がん（NSCLC） 患者のファーストライン治療で3種類の分子標的治療薬の組み合わせを使用した新規治療アプローチに対し、臨床試験開始の承認を受けました。SPRING（Survival Prolongation by Rationale Innovative...
View ArticleClik here to view.
Takeda and Shattuck Labs Announce Research Collaboration to Explore Agonist...
CAMBRIDGE, Mass. & AUSTIN, Texas Takeda Pharmaceutical Company Limited (TSE: 4502) and Shattuck Labs, Inc. announced today that they have entered into a research collaboration to explore and...
View ArticleClik here to view.
CDISC Releases Therapeutic Area User Guide to Assist in Discovery of New...
AUSTIN, Texas According to the World Health Organization, prostate cancer is one of the five most common types of cancer to affect men globally. In an effort to improve research for prostate cancer,...
View ArticleClik here to view.
Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage...
SAN DIEGO Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of...
View ArticleClik here to view.
PREVENA™ Incision Management System Shown to Reduce Incisional Pain and...
SAN ANTONIO Recent results published in the American Journal of Perinatology demonstrated the reduction of post-surgical wound complications in obese patients undergoing cesarean delivery with...
View ArticleClik here to view.
PAREXEL and Osaka International Cancer Institute Form Alliance to Advance...
BOSTON & OSAKA, Japan PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they...
View ArticleClik here to view.
20/20’s Lung Cancer Detection Technology Launches in China
ROCKVILLE, Md. & SHANGHAI 20/20 GeneSystems, Inc. (www.2020gene.com) (“20/20”) released this week in China what is believed to be the world’s first machine learning algorithm commercialized for...
View ArticleClik here to view.
Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and...
View ArticleClik here to view.
Celularityが画期的な胎盤発見＆治療プラットフォームの開発を促進
米ニュージャージー州ウォーレン （ビジネスワイヤ） — 最近創業したバイオテクノロジー企業のCelularity,...
View ArticleClik here to view.
Masimo PVi®作为腹腔镜除脂手术期间目标指导补液治疗组成部分的功效研究
瑞士纳沙泰尔 (美国商业资讯) — Masimo (NASDAQ: MASI)今天发布了近期发表的一项研究成果，土耳其菲拉特大学的研究人员在该研究中评估了Masimo PVi®的功效，PVi 是呼吸周期期间灌注指数(Pi)动态变化的无创连续测量指标，它是腹腔镜除脂手术患者在机械通气条件下目标指导的补液治疗(GDFT)方案的基础1。...
View ArticleClik here to view.
腹腔鏡下肥満治療手術における目標指向型輸液療法の一部としてのMasimo PVi®の性能を検討した研究
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、トルコのFirat Universityの研究者らが最近発表した研究の知見について発表しました。この研究は、人工呼吸患者の腹腔鏡下肥満治療手術における目標指向型輸液療法（GDFT）プロトコルの基礎として、呼吸周期で発生する灌流指標（PI）の動的変化を非侵襲的かつ連続的に測定したMasimo...
View ArticleClik here to view.
未治療患者におけるNuwiq®の低免疫原性と優れた効力を実証する臨床データを公表
スイス・ラッヘン （ビジネスワイヤ） — オクタファルマは、未治療患者（PUP）をNuwiq®で治療する初の臨床試験となるNuProtect試験（GENA-05、NCT01712438）について、中間データが2017年8月16日に国際的に著名な医学誌「ヘモフィリア」の先行公開論文として公表されたことを発表します。...
View ArticleClik here to view.
Celularity, Inc.加快突破性胎盘发现和治疗平台
新泽西州沃伦 (美国商业资讯) — Celularity, Inc.是一家新成立的生物技术公司，该公司今天宣布，它在加快细胞及组织再生治疗药物，以满足癌症和慢性及退行性疾病领域未获满足的医疗需求。Celularity已完成A轮融资，投资方来自数家生物制药公司，包括Sorrento Therapeutics、United Therapeutics Corporation和Human...
View ArticleClik here to view.
已发表的临床数据显示，Nuwiq®对既往未曾治疗的患者免疫原性低、有效性卓著
瑞士拉亨 (美国商业资讯) — Octapharma欣然宣布，NuProtect研究(GENA-05, NCT01712438)的中期数据已经发表：Nuwiq®治疗既往未曾治疗的患者(PUP)的首批临床数据于2017年8月16日作为预览论著发表于国际著名的医学杂志《血友病》(Haemophilia)。 NuProtect研究启动于2013年3月，旨在研究Nuwiq® 对重症血友病A...
View ArticleClik here to view.
Astex Pharmaceuticals Celebrates as Cancer Drug Receives Marketing Approval...
CAMBRIDGE, England Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central...
View ArticleClik here to view.
Kyowa Hakko Kirin Co., Ltd.: US Food and Drug Administration Grants...
TOKYO Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151)(President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announced that U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
View ArticleClik here to view.
MOLOGEN AG and Chinese iPharma Ltd. signed binding term sheet for a...
BERLIN The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced today the signing of a binding term sheet that defines the framework for...
View Article